Area of research
Surgery · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Anesthesia and Pain Management, Nausea and vomiting management, Cardiac, Anesthesia and Surgical Outcomes, and Enhanced Recovery After Surgery.
Dual-channel fluorescent probe for discriminative detection of H2S and N2H4: Exploring sensing mechanism and real-time applications
A coumarin derivative-based turn-on fluorescent probe for real-time applications of hydrazine detection in environment and bioimaging
Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.
Quinoline-derived electron-donating/withdrawing fluorophores for hydrazine detection and applications in environment and bioimaging
Insights of keratin geometry from agro-industrial wastes: A comparative computational and experimental assessment
Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES.
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with<i>EGFR</i>-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma
Conformational change of Dishevelled plays a key regulatory role in the Wnt signaling pathways